Irving Dark is a biometrics Subject Matter Expert with over 30 years of industry experience guiding drug, biologic, and medical device products successfully through the development process. Currently, he is on the Board of Directors of MMS, Founder/Managing Director of Sun Rock Partners, and an Affiliate Partner at Lindsay Goldberg.

Irving established the Clinical Research Services division at Cytel and served as Senior Vice President of Project Based Services for over 13 years. Prior to Cytel, he held senior leadership roles at Veristat, where he established and oversaw several core business units.

Earlier in his career, Irving held key positions at PAREXEL, where he managed Phase I – III clinical trials in the US, South America, Europe and Asia. Major therapeutic areas of projects included: lipid-lower agent (CRESTOR®), HIV (NELFINAVIR®), acromegaly (SOMATULINE®), and Stroke.

Irving has an in-depth knowledge of clinical development and biometrics, is co-author of numerous published clinical studies, and a DIA invited speaker. Irving holds Bachelor of Arts in Economics from the University of Rhode Island.

Suggested For You

perspectives

July 8th, 2025

Guidance for Working with External Data Vendors – Getting from LPLV to Database Lock Faster

perspectives

July 1st, 2025

Why Real-Time Data Access Matters (and How to Make the Most of It)

webinar

July 31st, 2025

Design, Data, and Decisions in Oncology Trials

perspectives

June 24th, 2025

Why Now Is the Time for Specialized, Data-Focused CRO Partners

news

June 19th, 2025

MMS Wins in the 2025 Fierce CRO Awards for Excellence in Client Service and Partnership and Dr. Uma Sharma Named CRO Champion 

perspectives

June 17th, 2025

Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise

regulatory intelligence

June 16th, 2025

Key MedDRA Coding Gaps Highlighted at the ISCTM 2025 Scientific Meeting

perspectives

June 10th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors